Leslie A Andritsos MD

Leslie A Andritsos MD
Assoc Professor - ClinicalCollege of Medicineandritsos.1@osu.edu
B307 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-3802Fax: 614-293-7526
  • Leukemia Research

Research Description

Dr. Andritsos' research interests include: Chronic Lymphocytic Leukemia (CLL), bone marrow transplant

Current Publications

  • El-Gamal D, Williams K, LaFollette T, Cannon M, Blachly JS, Zhong Y, Woyach J, Williams E, Awan F, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JCPKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates pre-clinical activity in CLL.Blood in press 7/7/2014
  • Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Von Hoff D, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJMitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.Leukemia in press 7/3/2014
  • Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy NThe CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.Leukemia 28 1501-10 7/1/2014
  • Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JCImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.Leukemia 28 1365-8 6/1/2014
  • Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM, Jaglowski S, Penza S, Andritsos LA, Devine SMAprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.Support Care Cancer in press 5/17/2014
  • Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SMAn effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.Bone Marrow Transplant in press 5/5/2014
  • Zhong Y, El-Gamal D, Dubovsky JA, Beckwith KA, Harrington BK, Williams KE, Goettl VM, Jha S, Mo X, Jones JA, Flynn JM, Maddocks KJ, Andritsos LA, McCauley D, Shacham S, Kauffman M, Byrd JC, Lapalombella RSelinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.Leukemia 28 1158-63 5/1/2014
  • Patterson AT, Andritsos L, Allen CM, Gru A, Kaffenberger BHMultifocal epithelial hyperplasia (Heck disease) in a patient with chronic lymphocytic leukemia.J Cutan Pathol in press 4/22/2014
  • Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RRA phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.Blood 123 1302-8 2/27/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy NLymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.Blood 122 3308-16 11/7/2013
  • Abandeh FI, Lustberg M, Devine S, Elder P, Andritsos L, Martin SIOutcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.Bone Marrow Transplant 48 1554-7 11/1/2013
  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JCIbrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood 122 2539-49 10/10/2013
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37 1195-9 10/1/2013
  • Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5 723-35 9/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • Kaffenberger BH, Wong HK, Jarjour W, Andritsos LARemission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation.J Am Acad Dermatol 68 489-92 3/1/2013
  • Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JCCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.PLoS One 8 e76607 1/1/2013
  • Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LAComplex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Br J Haematol 159 82-7 10/1/2012
  • Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JCER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood 120 1262-73 8/9/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu